- Home
- Publications
- Publication Search
- Publication Details
Title
Sorafenib: A Review in Hepatocellular Carcinoma
Authors
Keywords
Overall Survival, Sorafenib, Tace, Median Overall Survival, National Comprehensive Cancer Network
Journal
Targeted Oncology
Volume 12, Issue 2, Pages 243-253
Publisher
Springer Nature
Online
2017-03-15
DOI
10.1007/s11523-017-0484-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma
- (2016) Ann-Lii Cheng et al. HEPATOLOGY
- Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance).
- (2016) Ghassan K. Abou-Alfa et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study
- (2016) Shuichi Kaneko et al. JOURNAL OF GASTROENTEROLOGY
- Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON
- (2016) Masatoshi Kudo et al. JOURNAL OF GASTROENTEROLOGY
- Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study
- (2016) Jorge A. Marrero et al. JOURNAL OF HEPATOLOGY
- Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial
- (2016) Riccardo Lencioni et al. JOURNAL OF HEPATOLOGY
- Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study
- (2016) Masatoshi Kudo et al. LIVER INTERNATIONAL
- TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON
- (2016) Jean-François Geschwind et al. RADIOLOGY
- Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?
- (2016) Sandrine Faivre et al. Targeted Oncology
- Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma
- (2016) Supritha G. Swamy et al. Targeted Oncology
- Impact of Diabetes on Outcomes of Sorafenib Therapy for Hepatocellular Carcinoma
- (2016) Giovan Giuseppe Di Costanzo et al. Targeted Oncology
- Challenges of advanced hepatocellular carcinoma
- (2016) Stefano Colagrande et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Real-Life Experience of Sorafenib Treatment for Hepatocellular Carcinoma in Korea: From GIDEON Data
- (2016) Do Young Kim et al. Cancer Research and Treatment
- Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma
- (2015) Jiang Chen et al. CANCER LETTERS
- Molecular Mechanism and Prediction of Sorafenib Chemoresistance in Human Hepatocellular Carcinoma
- (2015) Naoshi Nishida et al. DIGESTIVE DISEASES
- Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study
- (2015) Bruno Daniele et al. Future Oncology
- Decisiones terapéuticas en el tratamiento del carcinoma hepatocelular y patrones de uso de sorafenib. Resultados del estudio internacional observacional GIDEON en España
- (2015) Juan Turnes et al. Gastroenterologia y Hepatologia
- Liver function assessment according to the Albumin–Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma
- (2015) Sadahisa Ogasawara et al. INVESTIGATIONAL NEW DRUGS
- Randomized Controlled Trial of the Prophylactic Effect of Urea-Based Cream on Sorafenib-Associated Hand-Foot Skin Reactions in Patients With Advanced Hepatocellular Carcinoma
- (2015) ZhengGang Ren et al. JOURNAL OF CLINICAL ONCOLOGY
- SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma
- (2015) Andrew X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
- (2015) Calin Cainap et al. JOURNAL OF CLINICAL ONCOLOGY
- Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
- (2015) Philip J. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- P1338 : An international observational study to assess the use of sorafenib after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC): optimis
- (2015) M. Peck-Radosavljevic et al. JOURNAL OF HEPATOLOGY
- Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study
- (2015) Masahito Nakano et al. Cancer Medicine
- Use of Transarterial Chemoembolization (TACE) and Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: US Regional Analysis of the GIDEON Registry
- (2015) Jean-Francois H. Geschwind et al. Liver Cancer
- EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2015) et al. JOURNAL OF HEPATOLOGY
- Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design
- (2014) J. M. Llovet et al. CLINICAL CANCER RESEARCH
- Pro-apoptotic Sorafenib signaling in murine hepatocytes depends on malignancy and is associated with PUMA expression in vitro and in vivo
- (2014) R Sonntag et al. Cell Death & Disease
- Selection and management of hepatocellular carcinoma patients with sorafenib: recommendations and opinions from an Italian liver unit
- (2013) Salvatore D’Angelo et al. Future Oncology
- Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity
- (2013) Mei-Ling Chen et al. INTERNATIONAL JOURNAL OF CANCER
- GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis
- (2013) R. Lencioni et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
- (2013) Philip J. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
- (2013) Ann-Lii Cheng et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis
- (2012) T. Pressiani et al. ANNALS OF ONCOLOGY
- Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2012) C. Verslype et al. ANNALS OF ONCOLOGY
- Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma
- (2012) J. M. Llovet et al. CLINICAL CANCER RESEARCH
- Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia–Pacific trial
- (2012) Ann-Lii Cheng et al. EUROPEAN JOURNAL OF CANCER
- First interim analysis of the GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) non-interventional study
- (2012) R. Lencioni et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses
- (2012) Jean-Luc Raoul et al. JOURNAL OF HEPATOLOGY
- Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
- (2012) Jordi Bruix et al. JOURNAL OF HEPATOLOGY
- Transarterial Chemoembolization Plus Sorafenib: A Sequential Therapeutic Scheme for HCV-Related Intermediate-Stage Hepatocellular Carcinoma: A Randomized Clinical Trial
- (2012) D. Sansonno et al. ONCOLOGIST
- Sorafenib Dose Escalation in the Treatment of Advanced Hepatocellular Carcinoma
- (2012) Jeong Eun Kim et al. ONCOLOGY
- Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score
- (2011) A. Hollebecque et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma
- (2011) Masatoshi Kudo et al. EUROPEAN JOURNAL OF CANCER
- Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy
- (2011) Massimo Iavarone et al. HEPATOLOGY
- Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma
- (2011) Wei-Tien Tai et al. JOURNAL OF HEPATOLOGY
- Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model
- (2011) Mengde Cao et al. LABORATORY INVESTIGATION
- Sorafenib Overcomes TRAIL Resistance of Hepatocellular Carcinoma Cells through the Inhibition of STAT3
- (2010) K.-F. Chen et al. CLINICAL CANCER RESEARCH
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now